Cargando…

2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study

BACKGROUND: Letermovir (LTV) for CMV prophylaxis in allogeneic hematopoietic cell transplant (HCT) recipients has decreased utilization of broad-spectrum antivirals for CMV, which may result in more frequent reactivation of herpesviruses not targeted by LTV. We hypothesized that the cumulative incid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kampouri, Eleftheria, Krantz, Elizabeth M, Zamora, Danniel, Kimball, Louise E, Kiem, Erika, Lovas, Erika A, Blazevic, Rachel, Stevens-Ayers, Terry L, Huang, Meei-Li, Masumi, Ueda Oshima, Jerome, Keith R, Zerr, Danielle M, Boeckh, Michael J, Hill, Joshua A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752656/ http://dx.doi.org/10.1093/ofid/ofac492.1730

Ejemplares similares

20. Risk Factors for Breakthrough Cytomegalovirus (CMV) Infection and De Novo Resistance in Hematopoietic Cell Transplantation (HCT) Recipients Receiving Letermovir Prophylaxis
por: Zamora, Danniel, et al.
Publicado: (2021)

194. Combinatorial Polyfunctionality Analysis of Antigen-specific T-cell Subsets (COMPASS) as a Predictor for Clinically Significant CMV Infection in the Letermovir Era
por: Zamora, Danniel, et al.
Publicado: (2020)

2591. The Role of Neutralizing Antibodies (nAb) Against Cytomegalovirus (CMV) Epithelial Cell-entry in Patients with Self-limited (SL) CMV infection after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2019)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa
por: Adjei, Andrew A, et al.
Publicado: (2008)

Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients
por: Rasmussen, NS, et al.
Publicado: (2015)

Co-infections of human herpesviruses (CMV, HHV-6, HHV-7 and EBV) in non-transplant acute leukemia patients undergoing chemotherapy
por: Handous, Imene, et al.
Publicado: (2020)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

1897. Letermovir Salvage for Complicated Cases of Resistant CMV
por: Turner, Nicholas, et al.
Publicado: (2018)

491. Characterizing the Association of Pre-Existing Cytomegalovirus (CMV)-specific Humoral Immunity with CMV Reactivation Risk after Hematopoietic Cell Transplantation (HCT)
por: Zamora, Danniel, et al.
Publicado: (2022)

Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient
por: Koepf, Uta S, et al.
Publicado: (2020)

Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation
por: Ueda Oshima, Masumi, et al.
Publicado: (2023)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients
por: Papadopoulou, Anastasia, et al.
Publicado: (2013)

Frequency divider PS/RF-LL 2109
por: Bento, J, et al.
Publicado: (1996)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Adenoid Hypertrophy Risk in Children Carriers of G-1082A Polymorphism of IL-10 Infected with Human Herpes Virus (HHV6, EBV, CMV)
por: Lomaeva, Iuliia, et al.
Publicado: (2022)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders
por: Sanchez, Sandra, et al.
Publicado: (2020)

1751. The Impact of Prophylactic Systemic Antibiotics (PSA) on Cytomegalovirus (CMV) Infection: A Post-hoc Analysis of a Randomized Controlled Trial (RCT) in Hematopoietic Cell Transplantation (HCT) Recipients
por: Zamora, Danniel, et al.
Publicado: (2019)

Post-mortem detection of six human herpesviruses (HSV-1, HSV-2, VZV, EBV, CMV, HHV-6) in trigeminal and facial nerve ganglia by PCR
por: Ptaszyńska-Sarosiek, Iwona, et al.
Publicado: (2019)

Evaluation of Epstein-Barr virus (EBV) and human herpes virus-8 (HHV-8) in HIV-associated persistent generalized lymphadenopathy (PGL)
por: Ayers, LW, et al.
Publicado: (2009)

580. Refractory and Resistant CMV Infections in Hematopoietic Cell Transplant Recipients in the Letermovir Primary Prophylaxis Era
por: Sassine, Joseph, et al.
Publicado: (2020)

Combined Therapy with Intravenous Immunoglobulins, Letermovir and (Val-)Ganciclovir in Complicated Courses of CMV-Infection in Transplant Recipients
por: Di Cristanziano, Veronica, et al.
Publicado: (2021)

922. The Impact of Clinically Significant CMV Infections on Other Viral Infections in the Era of Letermovir Primary Prophylaxis
por: Spallone, Amy, et al.
Publicado: (2021)

EBV, HCMV, HHV6, and HHV7 Screening in Bone Marrow Samples from Children with Acute Lymphoblastic Leukemia
por: Morales-Sánchez, A., et al.
Publicado: (2014)

Viral Infection and Autophagy Dysregulation: The Case of HHV-6, EBV and KSHV
por: Romeo, Maria Anele, et al.
Publicado: (2020)

HHV-8 and EBV Positive Lymphoproliferative Disease: A Challenging Case
por: Bülbül, Göksenil, et al.
Publicado: (2022)

2296. Development of a Sequencing-Based Assay for Detection of CMV Antiviral Resistance Mutations to Letermovir in UL56
por: Grantham, James, et al.
Publicado: (2018)

1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients
por: Abidi, Maheen, et al.
Publicado: (2020)

The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients
por: Sourisseau, Mathilde, et al.
Publicado: (2022)

The prevalence of EBV and CMV DNA in epithelial ovarian cancer
por: Ingerslev, Kasper, et al.
Publicado: (2019)

HPV Infection, but Not EBV or HHV-8 Infection, Is Associated with Salivary Gland Tumours
por: Hühns, Maja, et al.
Publicado: (2015)

S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
por: Xuying, Pei, et al.
Publicado: (2023)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda
por: Tumwine, Lynnette K, et al.
Publicado: (2010)

HHV8/EBV Coinfection Lymphoproliferative Disorder: Rare Entity with a Favorable Outcome
por: Bacha, Dhouha, et al.
Publicado: (2017)

Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV
por: Liu, Chih-Yi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_34qo7q3btnibp13a7c30m2a7ni